Report Overview

Germanys Prostate Cancer market size stood at around USD XX.X billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of around XX.X% during the forecast period.

In 2017, 360,916 cases of prostate cancer have been diagnosed in Germany, being highest in the entire European market, and still the prevalence of prostate cancer is evident in the country. The drug treatment of prostate cancer has evolved quickly over the last few years, with the metastatic castrate-resistant prostate cancer (mCRPC) situation becoming more crowded and competitive.



Market Driving and Restraining Factors

Market Drivers

The rising incidence of prostate cancer is recognized as a major driver for the growth of the prostate cancer market during the forecast period. Some other drivers are the increasing geriatric population base, growing demand for novel drugs. Although the exact cause of prostate cancer is not known, factors associated with it include overweight, obesity, and history of any other tumorous growth. Even patients with cardiovascular diseases are prone to metastasis of cancer. Thus, the rising incidence rate of the above-mentioned conditions is also driving the market growth.

Restraining Factors

Factors restraining market growth include high treatment costs and low patient compliance due to complicated treatment methods.